Adlai Nortye doses first patient in weekly arm of Phase 1 AN9025 pan-RAS inhibitor trial
ANL•First patient dosed in weekly dosing arm
Adlai Nortye dosed the first U.S. patient in the intermittent weekly arm of its global Phase 1 trial for pan-RAS(ON) inhibitor AN9025.
Both once-daily and once-weekly dose-escalation arms are enrolling in advanced or metastatic solid tumors with RAS mutations.
Management targets initial Phase 1 dose-escalation data from the once-daily arm in 1H27, with a potential early look at weekly dosing.
